中国外骨骼机器人获得CFDA注册证 开启智慧康复新模式

2018-06-30 佚名 健康界

外骨骼机器人艾康、艾动于北京获得CFDA注册证,成为中国首个通过CFDA认证的下肢外骨骼机器人。在此之前,大艾外骨骼康复机器人被并评定为北京市首个二类创新医疗器械,也是实行第二类创新医疗器械“绿色通道”审评审批政策后全国第一个二类创新医疗器械。而此次大艾机器人通过CFDA认证进入市场销售,是国内AI运动康复领域的突破性成就,标志着国内下肢外骨骼机器人已经从研发阶段转化为产业化量产阶段,大大推动了运

外骨骼机器人艾康、艾动于北京获得CFDA注册证,成为中国首个通过CFDA认证的下肢外骨骼机器人。在此之前,大艾外骨骼康复机器人被并评定为北京市首个二类创新医疗器械,也是实行第二类创新医疗器械“绿色通道”审评审批政策后全国第一个二类创新医疗器械。而此次大艾机器人通过CFDA认证进入市场销售,是国内AI运动康复领域的突破性成就,标志着国内下肢外骨骼机器人已经从研发阶段转化为产业化量产阶段,大大推动了运动康复领域产业发展的进程。

外骨骼机器人在康复临床应用中拥有传统设备所不具备的优势。美国医学科学院院士、南京医科大学康复学科带头人励建安教授总结大艾CFDA临床试验时说:“外骨骼机器人对于失去站立或行走功能的患者,提供了直立行走康复训练新方式,可以帮助患者高频率长时间保持仿人行走运动训练,这在过去是没有办法实现的。因此我们在验证其安全性和有效性的同时,发现了许多预料之外的、新的治疗效果,在临床试验中,外骨骼机器人带动了患者运动功能、消化功能、二便功能、心理状态的有效改善。另外,我们也发现了其它一些值得深层次研究的治疗效果,患者通过外骨骼机器人行走训练,肌张力得到明显下降,重新获得了行走能力,这给康复领域带来了新的治疗方式和思维。”大艾机器人在临床试验过程中,也不断验证这些发现,并针对过去运动康复领域的更多疑难痛点,如偏瘫患者等,在改善行走姿态、综合运动能力以及肌力、肌张力方面,也展现出了突出的疗效。

专注康复、助残、养老领域,高端医疗机器人研发制造生产服务于一体,着力于采用医工结合方式,为下肢运动功能障碍康复领域提供先进诊疗方案。大艾此次通过CFDA认证的外骨骼机器人产品,不仅为不同康复训练时期的患者提供了不同的康复训练模式,还能通过大数据应用和智能化控制技术,帮助减轻医生康复训练工作强度,提升康复训练效率,帮助制定个性化康复训练处方,是智慧康复产品领域的杰出代表。

成为第一个获得CFDA认证的外骨骼机器人企业并非偶然。据悉,其创业研发团队以北航教授帅梅为核心,在机器人运动康复领域就获得过科技部“十二五”支撑计划数字医疗项目、国家自然科学基金项目、北京重大科技计划项目的研发支持,其研发成果更是在各类国际、国内创新创业大赛中斩获大奖。

大艾机器人自成立以来就备受投资人的青睐,成立初期,大艾便获得了首都科技发展集团的天使轮投资1200万元。2018年1月份大艾机器人完成Pre-A轮数千万人民币的融资,由金科君创资本领投,硅谷天堂资产管理集团跟投。据悉,大艾机器人即将启动A轮融资,跨入公司发展新阶段。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1994144, encodeId=1b7d199414443, content=<a href='/topic/show?id=119e43021eb' target=_blank style='color:#2F92EE;'>#外骨骼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43021, encryptionId=119e43021eb, topicName=外骨骼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Wed Aug 01 17:09:00 CST 2018, time=2018-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890714, encodeId=43721890e147b, content=<a href='/topic/show?id=a867452008' target=_blank style='color:#2F92EE;'>#CFDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4520, encryptionId=a867452008, topicName=CFDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Wed Mar 06 23:09:00 CST 2019, time=2019-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032016, encodeId=ab46203201692, content=<a href='/topic/show?id=de0e4943257' target=_blank style='color:#2F92EE;'>#康复新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49432, encryptionId=de0e4943257, topicName=康复新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Tue Apr 09 19:09:00 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1322029, encodeId=3001132202993, content=<a href='/topic/show?id=890c611854e' target=_blank style='color:#2F92EE;'>#机器人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61185, encryptionId=890c611854e, topicName=机器人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Mon Jul 02 07:09:00 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556824, encodeId=3242155682448, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64956, encryptionId=e4016495635, topicName=注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c52c14833361, createdName=zhyy93, createdTime=Mon Jul 02 07:09:00 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583139, encodeId=fdef158313912, content=<a href='/topic/show?id=f6e1611840d' target=_blank style='color:#2F92EE;'>#机器#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61184, encryptionId=f6e1611840d, topicName=机器)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13dc16973127, createdName=ms6279672939590805, createdTime=Mon Jul 02 07:09:00 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328254, encodeId=557d32825453, content=厉害了.我国医生们., beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sat Jun 30 17:20:06 CST 2018, time=2018-06-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1994144, encodeId=1b7d199414443, content=<a href='/topic/show?id=119e43021eb' target=_blank style='color:#2F92EE;'>#外骨骼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43021, encryptionId=119e43021eb, topicName=外骨骼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Wed Aug 01 17:09:00 CST 2018, time=2018-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890714, encodeId=43721890e147b, content=<a href='/topic/show?id=a867452008' target=_blank style='color:#2F92EE;'>#CFDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4520, encryptionId=a867452008, topicName=CFDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Wed Mar 06 23:09:00 CST 2019, time=2019-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032016, encodeId=ab46203201692, content=<a href='/topic/show?id=de0e4943257' target=_blank style='color:#2F92EE;'>#康复新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49432, encryptionId=de0e4943257, topicName=康复新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Tue Apr 09 19:09:00 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1322029, encodeId=3001132202993, content=<a href='/topic/show?id=890c611854e' target=_blank style='color:#2F92EE;'>#机器人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61185, encryptionId=890c611854e, topicName=机器人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Mon Jul 02 07:09:00 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556824, encodeId=3242155682448, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64956, encryptionId=e4016495635, topicName=注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c52c14833361, createdName=zhyy93, createdTime=Mon Jul 02 07:09:00 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583139, encodeId=fdef158313912, content=<a href='/topic/show?id=f6e1611840d' target=_blank style='color:#2F92EE;'>#机器#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61184, encryptionId=f6e1611840d, topicName=机器)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13dc16973127, createdName=ms6279672939590805, createdTime=Mon Jul 02 07:09:00 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328254, encodeId=557d32825453, content=厉害了.我国医生们., beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sat Jun 30 17:20:06 CST 2018, time=2018-06-30, status=1, ipAttribution=)]
    2019-03-06 stfoxst
  3. [GetPortalCommentsPageByObjectIdResponse(id=1994144, encodeId=1b7d199414443, content=<a href='/topic/show?id=119e43021eb' target=_blank style='color:#2F92EE;'>#外骨骼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43021, encryptionId=119e43021eb, topicName=外骨骼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Wed Aug 01 17:09:00 CST 2018, time=2018-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890714, encodeId=43721890e147b, content=<a href='/topic/show?id=a867452008' target=_blank style='color:#2F92EE;'>#CFDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4520, encryptionId=a867452008, topicName=CFDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Wed Mar 06 23:09:00 CST 2019, time=2019-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032016, encodeId=ab46203201692, content=<a href='/topic/show?id=de0e4943257' target=_blank style='color:#2F92EE;'>#康复新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49432, encryptionId=de0e4943257, topicName=康复新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Tue Apr 09 19:09:00 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1322029, encodeId=3001132202993, content=<a href='/topic/show?id=890c611854e' target=_blank style='color:#2F92EE;'>#机器人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61185, encryptionId=890c611854e, topicName=机器人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Mon Jul 02 07:09:00 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556824, encodeId=3242155682448, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64956, encryptionId=e4016495635, topicName=注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c52c14833361, createdName=zhyy93, createdTime=Mon Jul 02 07:09:00 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583139, encodeId=fdef158313912, content=<a href='/topic/show?id=f6e1611840d' target=_blank style='color:#2F92EE;'>#机器#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61184, encryptionId=f6e1611840d, topicName=机器)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13dc16973127, createdName=ms6279672939590805, createdTime=Mon Jul 02 07:09:00 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328254, encodeId=557d32825453, content=厉害了.我国医生们., beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sat Jun 30 17:20:06 CST 2018, time=2018-06-30, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1994144, encodeId=1b7d199414443, content=<a href='/topic/show?id=119e43021eb' target=_blank style='color:#2F92EE;'>#外骨骼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43021, encryptionId=119e43021eb, topicName=外骨骼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Wed Aug 01 17:09:00 CST 2018, time=2018-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890714, encodeId=43721890e147b, content=<a href='/topic/show?id=a867452008' target=_blank style='color:#2F92EE;'>#CFDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4520, encryptionId=a867452008, topicName=CFDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Wed Mar 06 23:09:00 CST 2019, time=2019-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032016, encodeId=ab46203201692, content=<a href='/topic/show?id=de0e4943257' target=_blank style='color:#2F92EE;'>#康复新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49432, encryptionId=de0e4943257, topicName=康复新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Tue Apr 09 19:09:00 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1322029, encodeId=3001132202993, content=<a href='/topic/show?id=890c611854e' target=_blank style='color:#2F92EE;'>#机器人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61185, encryptionId=890c611854e, topicName=机器人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Mon Jul 02 07:09:00 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556824, encodeId=3242155682448, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64956, encryptionId=e4016495635, topicName=注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c52c14833361, createdName=zhyy93, createdTime=Mon Jul 02 07:09:00 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583139, encodeId=fdef158313912, content=<a href='/topic/show?id=f6e1611840d' target=_blank style='color:#2F92EE;'>#机器#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61184, encryptionId=f6e1611840d, topicName=机器)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13dc16973127, createdName=ms6279672939590805, createdTime=Mon Jul 02 07:09:00 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328254, encodeId=557d32825453, content=厉害了.我国医生们., beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sat Jun 30 17:20:06 CST 2018, time=2018-06-30, status=1, ipAttribution=)]
    2018-07-02 xue8602
  5. [GetPortalCommentsPageByObjectIdResponse(id=1994144, encodeId=1b7d199414443, content=<a href='/topic/show?id=119e43021eb' target=_blank style='color:#2F92EE;'>#外骨骼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43021, encryptionId=119e43021eb, topicName=外骨骼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Wed Aug 01 17:09:00 CST 2018, time=2018-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890714, encodeId=43721890e147b, content=<a href='/topic/show?id=a867452008' target=_blank style='color:#2F92EE;'>#CFDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4520, encryptionId=a867452008, topicName=CFDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Wed Mar 06 23:09:00 CST 2019, time=2019-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032016, encodeId=ab46203201692, content=<a href='/topic/show?id=de0e4943257' target=_blank style='color:#2F92EE;'>#康复新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49432, encryptionId=de0e4943257, topicName=康复新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Tue Apr 09 19:09:00 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1322029, encodeId=3001132202993, content=<a href='/topic/show?id=890c611854e' target=_blank style='color:#2F92EE;'>#机器人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61185, encryptionId=890c611854e, topicName=机器人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Mon Jul 02 07:09:00 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556824, encodeId=3242155682448, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64956, encryptionId=e4016495635, topicName=注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c52c14833361, createdName=zhyy93, createdTime=Mon Jul 02 07:09:00 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583139, encodeId=fdef158313912, content=<a href='/topic/show?id=f6e1611840d' target=_blank style='color:#2F92EE;'>#机器#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61184, encryptionId=f6e1611840d, topicName=机器)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13dc16973127, createdName=ms6279672939590805, createdTime=Mon Jul 02 07:09:00 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328254, encodeId=557d32825453, content=厉害了.我国医生们., beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sat Jun 30 17:20:06 CST 2018, time=2018-06-30, status=1, ipAttribution=)]
    2018-07-02 zhyy93
  6. [GetPortalCommentsPageByObjectIdResponse(id=1994144, encodeId=1b7d199414443, content=<a href='/topic/show?id=119e43021eb' target=_blank style='color:#2F92EE;'>#外骨骼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43021, encryptionId=119e43021eb, topicName=外骨骼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Wed Aug 01 17:09:00 CST 2018, time=2018-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890714, encodeId=43721890e147b, content=<a href='/topic/show?id=a867452008' target=_blank style='color:#2F92EE;'>#CFDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4520, encryptionId=a867452008, topicName=CFDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Wed Mar 06 23:09:00 CST 2019, time=2019-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032016, encodeId=ab46203201692, content=<a href='/topic/show?id=de0e4943257' target=_blank style='color:#2F92EE;'>#康复新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49432, encryptionId=de0e4943257, topicName=康复新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Tue Apr 09 19:09:00 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1322029, encodeId=3001132202993, content=<a href='/topic/show?id=890c611854e' target=_blank style='color:#2F92EE;'>#机器人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61185, encryptionId=890c611854e, topicName=机器人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Mon Jul 02 07:09:00 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556824, encodeId=3242155682448, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64956, encryptionId=e4016495635, topicName=注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c52c14833361, createdName=zhyy93, createdTime=Mon Jul 02 07:09:00 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583139, encodeId=fdef158313912, content=<a href='/topic/show?id=f6e1611840d' target=_blank style='color:#2F92EE;'>#机器#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61184, encryptionId=f6e1611840d, topicName=机器)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13dc16973127, createdName=ms6279672939590805, createdTime=Mon Jul 02 07:09:00 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328254, encodeId=557d32825453, content=厉害了.我国医生们., beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sat Jun 30 17:20:06 CST 2018, time=2018-06-30, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1994144, encodeId=1b7d199414443, content=<a href='/topic/show?id=119e43021eb' target=_blank style='color:#2F92EE;'>#外骨骼#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43021, encryptionId=119e43021eb, topicName=外骨骼)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c30265, createdName=jiafufeng@yaho, createdTime=Wed Aug 01 17:09:00 CST 2018, time=2018-08-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1890714, encodeId=43721890e147b, content=<a href='/topic/show?id=a867452008' target=_blank style='color:#2F92EE;'>#CFDA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=4520, encryptionId=a867452008, topicName=CFDA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1a19115, createdName=stfoxst, createdTime=Wed Mar 06 23:09:00 CST 2019, time=2019-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2032016, encodeId=ab46203201692, content=<a href='/topic/show?id=de0e4943257' target=_blank style='color:#2F92EE;'>#康复新#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49432, encryptionId=de0e4943257, topicName=康复新)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=fc8528, createdName=clmlylxy, createdTime=Tue Apr 09 19:09:00 CST 2019, time=2019-04-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1322029, encodeId=3001132202993, content=<a href='/topic/show?id=890c611854e' target=_blank style='color:#2F92EE;'>#机器人#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61185, encryptionId=890c611854e, topicName=机器人)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d139492, createdName=xue8602, createdTime=Mon Jul 02 07:09:00 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1556824, encodeId=3242155682448, content=<a href='/topic/show?id=e4016495635' target=_blank style='color:#2F92EE;'>#注册#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64956, encryptionId=e4016495635, topicName=注册)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c52c14833361, createdName=zhyy93, createdTime=Mon Jul 02 07:09:00 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1583139, encodeId=fdef158313912, content=<a href='/topic/show?id=f6e1611840d' target=_blank style='color:#2F92EE;'>#机器#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61184, encryptionId=f6e1611840d, topicName=机器)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=13dc16973127, createdName=ms6279672939590805, createdTime=Mon Jul 02 07:09:00 CST 2018, time=2018-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=328254, encodeId=557d32825453, content=厉害了.我国医生们., beContent=null, objectType=article, channel=null, level=null, likeNumber=42, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=60791943465, createdName=1e0f8808m18(暂无匿称), createdTime=Sat Jun 30 17:20:06 CST 2018, time=2018-06-30, status=1, ipAttribution=)]
    2018-06-30 1e0f8808m18(暂无匿称)

    厉害了.我国医生们.

    0

相关资讯

中国自主研发生产的抗癌药,可治疗晚期转移性肠癌

首个独立由中国人发明、中国医生研究、中国企业研发的抗癌药“呋喹替尼”即将面世,可为接受过至少两次化疗方案,但仍发生疾病进展的转移性结直肠癌患者带来希望,在临床研究中被证实可显着延长患者的生存期。

外资药企纷纷“抢滩” 中国 “钱景”究竟如何

在中国医药市场,国际上知名的制药商和投资者可谓群贤毕至(All in),因为他们豪赌通过将创新性新药带给一直以来没什么选择的中国病人而大赚特赚。然而,中国的医疗体系与美国有很大不同,药企如何才能从在中国市场掘金?近日,美国医药媒体Stat刊文,邀请专家对中国的医保支付场景进行了分析勾勒。文章认为,中国在崛起为生物科技强国的同时,也将会变成应对药物定价棘手挑战的下一个前沿阵地,这篇文章也给我们

任胜利:2017年度我国SCI收录期刊引证指标概览

2017年度JCR共收录科技期刊8996种,相比2016年度的8858种增加138种,增幅为1.56%。 本年度中国大陆(China Mainland)计有192种期刊被收录,相比2016年度的179种增加13种,增幅为7.26%。 从影响因子的学科分区看,2017年度中国大陆地区期刊位列Q1区(“期刊分区”的分值为75.0—100)的期刊数量相对2016年度的31种上升至40种。 感谢蔡斐

一年新增150余家血透中心 看专家解读中国血透产业政策

前国家卫计委陆续印发医学影像诊断中心、医学检验实验室、血液净化机构、病理诊断中心4类独立设置医疗机构基本标准和管理规范,鼓励血透中心向民营资本开放。

急诊科建设,中国和新加坡太不一样了!

急诊科的工作结束了。对于急诊,有着复杂的感情,因为曾经在北京某医院的急诊工作过八个月。这种战斗中过来的生活,总是难以忘怀。写点东西,纪念一下曾经的急诊岁月。中国和新加坡的急诊科的建构有着很大的不同,最显着的有两点:分科的设置中国的急诊还是分的很细。护士分诊之后,可以决定病人是否去内科(某些医院有神经内科的急诊),普通外科,骨科,泌尿外科,耳鼻喉,眼科。而新加坡急诊科的医生都得来,急诊专科的医生是

J Infect:HPV疫苗本为舶来品 对中国女性的保护几何?

在世界范围内,宫颈癌是女性第四大常见癌症,是所有癌症中的第七大常见癌症。据最新的国家癌症统计数据,宫颈癌已成为中国女性的第八大杀手。已经确认,人乳头瘤病毒(HPV)是宫颈癌和宫颈上皮内瘤变的主要原因。迄今为止,已经确定了超过150种HPV。其中,12种HPV类型是与人类癌症相关的高风险类型,即16、18、31、33、35、39、45、51、52、56、58和59。